The clinical efficacy of modified electroconvulsive therapy combined with ziprasidone in female patients with refractory schizophrenia

Abstract

Objective To analyze the clinical efficacy of modified electroconvulsive therapy (MECT) combined with ziprasidone in female patients with refractory schizophrenia. Methods 74 female patients with refractory schizophrenia in our hospital from February 2016 to January 2017 were collected, and were randomly divided into two groups according to the SAS software package, 37 cases in each group. The drug group was treated with ziprasidone, and the combined treatment group was treated with MECT combined with ziprasidone. The clinical efficacy and treatment safety of the two groups were statistically analyzed. Results After 1 week of treatment, the PANSS psychopathology score, positive symptom score, and total PANSS score of the drug group and the combined treatment group were significantly decreased, with statistically significant differences (P 0.05). The incidence of adverse reactions during the treatment in the drug group was 29.73%, and that in the combined treatment group was 37.84%, without statistically significant difference (P>0.05). Conclusion Modified electroconvulsive therapy combined with ziprasidone in the treatment of female patients with refractory schizophrenia can get a better effect, and will not increase the adverse reactions. Key words: Electroconvulsive shock; Ziprasidone; Female; Refractory schizophrenia